Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study results from Wayne State University provide new insights into cancer vaccines
November 11th, 2008
According to recent research from the United States, " The development of Her-2 DNA vaccine has progressed through three phases that can be categorized as phase ''A'': the pursuit of Her-2 as a tumor-associated ''antigen'', phase ''B'': tilting the ''balance'' between tumor immunity and autoimmunity and phase ''C'': the on-going ''clinical trials''. Materials and methods In phase ''A'', a panel of human ErbB-2 or Her-2 plasmids were constructed to encode non-transforming Her-2 derivatives." "The immunogenicity and anti-tumor activity of Her-2 DNA vaccines were tested in human Her-2 transgenic mice with or without the depletion of regulatory T cells (Tregs). However,...
Source: Cancer Weekly (2008-11-11)
|
